{"schema_version":"secwatch.filing_event.v1","accession":"0001714899-25-000128","form_type":"8-K","ticker":"DNLI","cik":"0001714899","company_name":"Denali Therapeutics Inc.","filed_at":"2025-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.449535+00:00","generated_at":"2026-05-20T01:47:54.198288+00:00","sec_items":["1.01","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Denali Therapeutics elects Julian Baker as director; grants registration rights to Baker Brothers funds","bullets":["Julian C. Baker elected as Class II director; 98.0M votes for, 22.9M withheld.","Registration rights agreement with BBA Funds grants resale registration rights; company must file S-3 within 60 days of request.","Ratified Ernst & Young as independent auditor for FY2025; advisory say-on-pay approved with 90.2% of shares represented."],"urls":{"canonical":"https://secwatch.observer/filing/0001714899-25-000128","json":"https://secwatch.observer/filing/0001714899-25-000128.json","markdown":"https://secwatch.observer/filing/0001714899-25-000128.md","text":"https://secwatch.observer/filing/0001714899-25-000128.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000128/0001714899-25-000128-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000128/dnli-20250603.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T01:47:54.198288+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}